Clinical efficacy of levetiracetam in the treatment of children with febrile convulsion and its influence on immune function and relapse

Abstract

Objective \nTo investigate the clinical efficacy of levetiracetam in the treatment of children with febrile convulsion and its influence on immune function and relapse. \n \n \nMethods \n104 children with febrile convulsion admitted in our hospital from January 2016 to May 2017 were selected, and were divided into two groups by randomized double blind method, with 52 cases in each group. The control group was given routine medicine, and the observation group was treated with levetiracetam based on the control group. The clinical efficacy, serum neuron-specific enolase (NSE), S100 protein (S100B), immune function indexes, adverse reactions, and relapse were compared between the two groups. \n \n \nResults \nAfter treatment for 15 d, the total effective rate of the observation group 92.31%(48/52) was higher than that of the control group 71.15%(37/52), while the rate of convulsion relapse in the observation group 5.77%(3/52) was lower than that in the control group 23.08%(12/52) (P 0.05). \n \n \nConclusion \nLevetiracetam has definite clinical efficacy in the treatment of children with febrile convulsion, which can decrease the levels of serum NSE and S100B, increase immune function, and reduce the relapse rate, which is safe and reliable. \n \n \nKey words: \nChildren with febrile convulsion;\xa0Levetiracetam;\xa0Clinical efficacy;\xa0Immune function;\xa0Relapse rate